Kimberley Smith1, Richard P Mattick1, Raimondo Bruno2, Suzanne Nielsen1, Milton Cohen3, Gabrielle Campbell4, Briony Larance1, Michael Farrell1, Louisa Degenhardt5. 1. National Drug and Alcohol Research Centre, UNSW, Sydney, NSW 2052, Australia. 2. School of Medicine, University of Tasmania, Australia. 3. St Vincent's Clinical School, UNSW Medicine, UNSW, Australia. 4. National Drug and Alcohol Research Centre, UNSW, Sydney, NSW 2052, Australia. Electronic address: g.campbell@unsw.edu.au. 5. National Drug and Alcohol Research Centre, UNSW, Sydney, NSW 2052, Australia; School of Population and Global Health, University of Melbourne, Australia; Murdoch Children's Research Institute, Australia; Department of Global Health, School of Public Health, University of Washington, USA.
Abstract
BACKGROUND AND AIMS: Pharmaceutical opioid prescription rates are increasing globally, however knowledge of their long-term effects on mental health, in particular depression remains limited. This study aimed to identify factors associated with the onset of depression post-opioid use that differ to factors associated with depression post-pain. METHOD: Participants (N = 1418) were a national sample prescribed opioids for chronic non-cancer pain. Age at onset of depression, pain and commencement of opioid medications were collected via structured interview. RESULTS: Six in 10 (61%) reported lifetime depression; of those, almost half developed depression after pain and after they started opioid medications (48%). Variables associated with post-opioid depression included lower pain self-efficacy and poorer social support, younger onset of opioid use, and difficulties and concerns with opioid medications. CONCLUSIONS: The findings highlight the importance of monitoring for the emergence of mood dysfunction, particularly for those starting opioids for pain at a younger age, and consideration of psychological treatments that address self-efficacy that appears to be associated with post-opioid depression.
BACKGROUND AND AIMS: Pharmaceutical opioid prescription rates are increasing globally, however knowledge of their long-term effects on mental health, in particular depression remains limited. This study aimed to identify factors associated with the onset of depression post-opioid use that differ to factors associated with depression post-pain. METHOD:Participants (N = 1418) were a national sample prescribed opioids for chronic non-cancer pain. Age at onset of depression, pain and commencement of opioid medications were collected via structured interview. RESULTS: Six in 10 (61%) reported lifetime depression; of those, almost half developed depression after pain and after they started opioid medications (48%). Variables associated with post-opioid depression included lower pain self-efficacy and poorer social support, younger onset of opioid use, and difficulties and concerns with opioid medications. CONCLUSIONS: The findings highlight the importance of monitoring for the emergence of mood dysfunction, particularly for those starting opioids for pain at a younger age, and consideration of psychological treatments that address self-efficacy that appears to be associated with post-opioid depression.
Authors: Graves T Owen; Brian M Bruel; C M Schade; Maxim S Eckmann; Erik C Hustak; Mitchell P Engle Journal: Proc (Bayl Univ Med Cent) Date: 2018-01-08
Authors: Jeffrey F Scherrer; Joanne Salas; F David Schneider; Kathleen K Bucholz; Mark D Sullivan; Laurel A Copeland; Brian K Ahmedani; Thomas Burroughs; Patrick J Lustman Journal: J Affect Disord Date: 2016-12-21 Impact factor: 4.839
Authors: Sherry H Stewart; Annie Chinneck; Kara Thompson; Mohammad H Afzali; Raquel Nogueira-Arjona; Ioan T Mahu; Patricia J Conrod Journal: Front Psychiatry Date: 2021-04-27 Impact factor: 4.157
Authors: Jeffrey F Scherrer; Brian Ahmedani; Kirsti Autio; Lynn Debar; Patrick J Lustman; Lisa R Miller-Matero; Joanne Salas; Scott Secrest; Mark D Sullivan; Lauren Wilson; Sarah Skiold-Hanlin Journal: J Psychiatr Brain Sci Date: 2020-04-28